Erodible Polymer Particle Oral Vaccine Adjuvant

Tech ID: 24979 / UC Case 2015-253-0

Technology Description

Heliobacter pylori is a known cause of gastric cancer, and over half of the world’s population is infected with H. pylori. According to the World Health Organization, gastric cancer caused by H. pylori is the third leading cause of cancer mortality in the world. A novel nanoparticle adjuvant preparation has been developed which combines vaccination with an agent that enhances gastric inflammation, boosts immunity and improves clearance of the H. pylori. This novel strategy has been tested in vitro and in vivo (mouse studies).

Intellectual Property Info

A provisional patent application has been filed.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20180153984 06/07/2018 2015-253
Patent Cooperation Treaty Published Application 2016176558 11/03/2016 2015-253
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As